Skip to main content
news
REUTERS/Tingshu Wang

Cooley, CYL & Partners and DeHeng Law Offices have advised China’s Asymchem Laboratories on its HK$6.85 billion ($878 million) secondary listing in Hong Kong, with Latham & Watkins and JunHe representing the joint sponsors.

This is believed to be the biggest healthcare IPO in Hong Kong this year. The company has been listed on the Shenzhen Stock Exchange since 2016.

Asymchem is a Chinese contract development manufacturing organisation (CDMO) serving the global pharmaceutical industry. According to Frost & Sullivan, it is the world’s fifth-largest drug substance CDMO by revenue, and the largest China-based commercial stage chemical drug CDMO.

The Cooley team was led by partners Yiming Liu and Michael Yu.

 

To contact the editorial team, please email ALBEditor@thomsonreuters.com.

Related Articles

Deals

Khaitan, JSA, Hogan Lovells guide $515 mln Waaree IPO

by Nimitt Dixit |

Khaitan & Co has advised Waaree Energies, India's largest manufacturer and exporter of solar modules, on its $515 million initial public offering, with JSA Advocates & Solicitors and Hogan Lovells guiding the bookrunning lead managers.

Deals

CAM, Khaitan guide Adani-backed Renew Exim’s $380 mln ITD acquisition

by Nimitt Dixit |

Cyril Amarchand Mangaldas has advised Adani Group's Dubai-based firm Renew Exim DMCC on its acquisition of a 46.64 percent stake in ITD Cementation India for around $380 million from Italian-Thai Development Public Company, who was represented by Khaitan & Co.

Deals

CAM, AZB, SAM, Latham advise on landmark $1.3 bln Swiggy IPO

by Nimitt Dixit |

Cyril Amarchand Mangaldas is advising SoftBank-backed Indian food and grocery delivery giant Swiggy on its much-anticipated initial public offering worth $1.3 billion, with AZB & Partners and Latham & Watkins advising the bookrunning lead managers.